297 related articles for article (PubMed ID: 10209946)
1. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy.
Magnusson C; Baron JA; Correia N; Bergström R; Adami HO; Persson I
Int J Cancer; 1999 May; 81(3):339-44. PubMed ID: 10209946
[TBL] [Abstract][Full Text] [Related]
2. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases.
Vinogradova Y; Coupland C; Hippisley-Cox J
BMJ; 2020 Oct; 371():m3873. PubMed ID: 33115755
[TBL] [Abstract][Full Text] [Related]
3. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe.
Stahlberg C; Pedersen AT; Lynge E; Andersen ZJ; Keiding N; Hundrup YA; Obel EB; Ottesen B
Int J Cancer; 2004 May; 109(5):721-7. PubMed ID: 14999781
[TBL] [Abstract][Full Text] [Related]
4. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement.
Persson I; Weiderpass E; Bergkvist L; Bergström R; Schairer C
Cancer Causes Control; 1999 Aug; 10(4):253-60. PubMed ID: 10482483
[TBL] [Abstract][Full Text] [Related]
5. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution.
Norman RJ; Flight IH; Rees MC
Cochrane Database Syst Rev; 2000; (2):CD001018. PubMed ID: 10796730
[TBL] [Abstract][Full Text] [Related]
6. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden.
Olsson HL; Ingvar C; Bladström A
Cancer; 2003 Mar; 97(6):1387-92. PubMed ID: 12627501
[TBL] [Abstract][Full Text] [Related]
7. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.
Stanford JL; Weiss NS; Voigt LF; Daling JR; Habel LA; Rossing MA
JAMA; 1995 Jul; 274(2):137-42. PubMed ID: 7596001
[TBL] [Abstract][Full Text] [Related]
8. Exogenous progestins and breast cancer.
Stanford JL; Thomas DB
Epidemiol Rev; 1993; 15(1):98-107. PubMed ID: 8405216
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort.
Fournier A; Berrino F; Riboli E; Avenel V; Clavel-Chapelon F
Int J Cancer; 2005 Apr; 114(3):448-54. PubMed ID: 15551359
[TBL] [Abstract][Full Text] [Related]
10. Hormone replacement therapy and the risk of breast cancer.
Cuzick J
Eur J Cancer; 2008 Nov; 44(16):2344-9. PubMed ID: 18783940
[TBL] [Abstract][Full Text] [Related]
11. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
Collaborative Group on Hormonal Factors in Breast Cancer
Lancet; 2019 Sep; 394(10204):1159-1168. PubMed ID: 31474332
[TBL] [Abstract][Full Text] [Related]
12. Menopausal hormone therapy and cancer risk: An overestimated risk?
Simin J; Tamimi R; Lagergren J; Adami HO; Brusselaers N
Eur J Cancer; 2017 Oct; 84():60-68. PubMed ID: 28783542
[TBL] [Abstract][Full Text] [Related]
13. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
[TBL] [Abstract][Full Text] [Related]
14. Is breast cancer risk the same for all progestogens?
Stute P
Arch Gynecol Obstet; 2014 Aug; 290(2):207-9. PubMed ID: 24838289
[TBL] [Abstract][Full Text] [Related]
15. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk?
Trabert B; Wentzensen N; Yang HP; Sherman ME; Hollenbeck AR; Park Y; Brinton LA
Int J Cancer; 2013 Jan; 132(2):417-26. PubMed ID: 22553145
[TBL] [Abstract][Full Text] [Related]
16. Postmenopausal estrogen and progestin use in relation to breast cancer risk.
Newcomb PA; Titus-Ernstoff L; Egan KM; Trentham-Dietz A; Baron JA; Storer BE; Willett WC; Stampfer MJ
Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):593-600. PubMed ID: 12101105
[TBL] [Abstract][Full Text] [Related]
17. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108
[TBL] [Abstract][Full Text] [Related]
18. Progesterone receptors--animal models and cell signalling in breast cancer. Implications for breast cancer of inclusion of progestins in hormone replacement therapies.
Schairer C
Breast Cancer Res; 2002; 4(6):244-8. PubMed ID: 12473171
[TBL] [Abstract][Full Text] [Related]
19. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
Schairer C; Lubin J; Troisi R; Sturgeon S; Brinton L; Hoover R
JAMA; 2000 Jan; 283(4):485-91. PubMed ID: 10659874
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer and post-menopausal hormone therapy.
Kenemans P; Bosman A
Best Pract Res Clin Endocrinol Metab; 2003 Mar; 17(1):123-37. PubMed ID: 12763516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
